FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
US6995008B1
(en)
*
|
1994-03-07 |
2006-02-07 |
Merck & Co., Inc. |
Coordinate in vivo gene expression
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5736524A
(en)
*
|
1994-11-14 |
1998-04-07 |
Merck & Co.,. Inc. |
Polynucleotide tuberculosis vaccine
|
FR2732895B1
(fr)
*
|
1995-04-11 |
1997-05-16 |
Pasteur Merieux Serums Vacc |
Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6338852B1
(en)
|
1995-09-01 |
2002-01-15 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US20020165183A1
(en)
*
|
1999-11-29 |
2002-11-07 |
Hans Herweijer |
Methods for genetic immunization
|
US20070021364A1
(en)
*
|
1995-12-13 |
2007-01-25 |
Hans Herweijer |
Methods for genetic immunization
|
ZA973642B
(en)
*
|
1996-04-26 |
1997-11-25 |
Merck & Co Inc |
DNA vaccine formulations.
|
US5846946A
(en)
*
|
1996-06-14 |
1998-12-08 |
Pasteur Merieux Serums Et Vaccins |
Compositions and methods for administering Borrelia DNA
|
FR2751228B1
(fr)
*
|
1996-07-19 |
1998-11-20 |
Rhone Merieux |
Vaccin polynucleotidique bovin pour voie intradermique
|
FR2751225B1
(fr)
*
|
1996-07-19 |
1998-11-27 |
Rhone Merieux |
Formule de vaccin polynucleotidique aviaire
|
WO1998012332A1
(en)
*
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
AU6148798A
(en)
*
|
1997-02-07 |
1998-08-26 |
Vanderbilt University |
Synthetic genes for recombinant mycobacterium proteins
|
US6261281B1
(en)
*
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
CA2328180A1
(en)
*
|
1998-04-14 |
1999-10-21 |
Merck & Co., Inc. |
Needleless administration of polynucleotide formulations
|
ID29858A
(id)
|
1998-11-04 |
2001-10-18 |
Isis Innovation |
Uji diagnostik tuberkulosis
|
US8197461B1
(en)
|
1998-12-04 |
2012-06-12 |
Durect Corporation |
Controlled release system for delivering therapeutic agents into the inner ear
|
US6465633B1
(en)
|
1998-12-24 |
2002-10-15 |
Corixa Corporation |
Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
|
US7022320B1
(en)
|
1999-02-09 |
2006-04-04 |
Powderject Vaccines, Inc. |
Mycobacterium tuberculosis immunization
|
EP1165132B1
(en)
*
|
1999-04-08 |
2011-10-19 |
Intercell USA, Inc. |
Dry formulation for transcutaneous immunization
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
CN1379819A
(zh)
*
|
1999-06-28 |
2002-11-13 |
俄克拉荷马州医学研究基金会 |
具有催化活性的重组memapsin蛋白酶及其应用方法
|
US6514948B1
(en)
*
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
EP2278022A3
(en)
*
|
1999-11-01 |
2011-05-18 |
Novartis Vaccines and Diagnostics, Inc. |
Expression vectors, transfection systems, and method of use thereof
|
EP1230268B1
(en)
|
1999-11-18 |
2009-10-14 |
Pharmexa Inc. |
Heteroclitic analogs of class i epitopes
|
WO2001045639A2
(en)
*
|
1999-12-22 |
2001-06-28 |
The Ohio State University Research Foundation |
Methods for protecting against lethal infection with bacillus anthracis
|
FR2804028B1
(fr)
*
|
2000-01-21 |
2004-06-04 |
Merial Sas |
Vaccins adn ameliores pour animaux de rente
|
EP1253947A4
(en)
*
|
2000-01-31 |
2005-01-05 |
Univ California |
IMMUNOMODULATED POLYNUCLEOTIDES FOR THE TREATMENT OF INFECTIONS BY INTRA-CELLULAR DISEASES
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
US6613751B2
(en)
|
2000-02-23 |
2003-09-02 |
The Regents Of The University Of California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
AU2001259291B2
(en)
*
|
2000-04-28 |
2006-11-23 |
Aventis Pasteur Limited |
Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
|
US6590087B1
(en)
*
|
2000-05-25 |
2003-07-08 |
Johns Hopkins University |
whmD, an essential cell division gene from mycobacteria
|
WO2002004018A2
(en)
*
|
2000-07-10 |
2002-01-17 |
Colorado State University Research Foundation |
Mid-life vaccine and methods for boosting anti-mycobacterial immunity
|
ES2323407T3
(es)
|
2000-07-12 |
2009-07-15 |
Agensys, Inc. |
Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
|
AU8846601A
(en)
|
2000-08-28 |
2002-03-13 |
Agensys Inc |
Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
CA2425648A1
(en)
|
2000-10-19 |
2002-04-19 |
Epimmune Inc. |
Hla class i and ii binding peptides and their uses
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
PT1372708E
(pt)
*
|
2001-02-13 |
2008-09-29 |
Us Gov Sec Army |
Vacina para imunização transcutânea
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
EP1390075B1
(en)
*
|
2001-04-06 |
2012-01-18 |
The University of Chicago |
Chemotherapeutic induction of egr-1 promoter activity in gene therapy
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
WO2002083921A2
(en)
|
2001-04-10 |
2002-10-24 |
Agensys, Inc. |
Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
US7013940B2
(en)
*
|
2001-04-19 |
2006-03-21 |
Michelin Recherche Et Technique S.A. |
Device for attenuating cavity noise in a tire and wheel
|
JP4338402B2
(ja)
|
2001-05-22 |
2009-10-07 |
ユニバーシティ オブ シカゴ |
N4ウイルス一本鎖dna依存的rnaポリメラーゼ
|
US7604955B2
(en)
*
|
2001-08-13 |
2009-10-20 |
Swey-Shen Alex Chen |
Immunoglobulin E vaccines and methods of use thereof
|
JP2005505271A
(ja)
|
2001-09-06 |
2005-02-24 |
アジェンシス, インコーポレイテッド |
癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質
|
AR037038A1
(es)
|
2001-10-26 |
2004-10-20 |
Baylor College Medicine |
Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
|
CA2469310C
(en)
|
2001-12-11 |
2013-01-29 |
Advisys, Inc. |
Plasmid mediated supplementation for treating chronically ill subjects
|
AU2003201093A1
(en)
*
|
2002-01-18 |
2003-07-30 |
Inovio As |
Bispecific antibody dna constructs for intramuscular administration
|
WO2003064621A2
(en)
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
US20050267025A1
(en)
*
|
2002-02-01 |
2005-12-01 |
Ho John L |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
EP2221377B2
(en)
|
2002-02-01 |
2017-05-17 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
US20030199012A1
(en)
*
|
2002-02-01 |
2003-10-23 |
Ho John L. |
Compositions and methods for treatment of infectious and inflammatory diseases
|
US20070037769A1
(en)
*
|
2003-03-14 |
2007-02-15 |
Multicell Immunotherapeutics, Inc. |
Compositions and methods to treat and control tumors by loading antigen presenting cells
|
EP2258712A3
(en)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
|
JP2005526778A
(ja)
*
|
2002-03-15 |
2005-09-08 |
アストラル,インコーポレイテッド |
免疫調節性非コードrnaモチーフを用いて抗体及び主要組織適合性クラスi拘束性又はクラスii拘束性t細胞の応答を開始或いは増強させるための組成物及び方法
|
US7078037B2
(en)
*
|
2002-04-19 |
2006-07-18 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections
|
US20060094006A1
(en)
*
|
2002-05-01 |
2006-05-04 |
Genoveffa Franchini |
Immunotherapy regimens in hiv-infected patients
|
NZ537579A
(en)
|
2002-06-10 |
2006-10-27 |
Vaccinex Inc |
C35 peptide epitopes and their analogs
|
AU2003259109A1
(en)
*
|
2002-07-12 |
2004-02-02 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
US6916474B2
(en)
|
2002-07-15 |
2005-07-12 |
Board Of Regents, The University Of Texas System |
Antibodies with increased affinities for anthrax antigens
|
US20040029275A1
(en)
*
|
2002-08-10 |
2004-02-12 |
David Brown |
Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
|
EP2044948B1
(en)
|
2002-08-12 |
2013-10-30 |
Jennerex Biotherapeutics ULC |
Vaccinia viruses for use in treating cancer
|
AU2003243151A1
(en)
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
AU2003284239B2
(en)
*
|
2002-10-21 |
2008-08-21 |
Eisai Inc. |
Compositions and methods for treating human papillomavirus-mediated disease
|
EP1565200A4
(en)
|
2002-11-27 |
2009-06-24 |
Agensys Inc |
NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
|
EP1903056A3
(en)
|
2002-12-10 |
2008-05-07 |
Idm Pharma, Inc. |
HLA-A1, -A2 -A3, -A24, -B7, and -B44 binding peptides comprising tumor associated antigen epitopes, and compositions thereof
|
EP2343315A3
(en)
|
2003-02-10 |
2011-11-23 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
|
US7262027B2
(en)
*
|
2003-03-14 |
2007-08-28 |
Medical College Of Ohio |
Polypeptide and DNA immunization against Coccidioides spp. infections
|
AU2004225480A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Multicell Immunotherapeutics, Inc. |
Selected RNA motifs to include cell death and/or apoptosis
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
US20070037151A1
(en)
*
|
2003-04-28 |
2007-02-15 |
Babe Lilia M |
Cd4+ human papillomavirus (hpv) epitopes
|
ES2384622T3
(es)
|
2003-05-30 |
2012-07-10 |
Agensys, Inc. |
Variantes del antígeno de células madre de próstata (PSCA) y subsecuencias de las mismas
|
US20060240039A1
(en)
*
|
2003-06-13 |
2006-10-26 |
Isis Innovation Limited |
Vaccines
|
CN1894581B
(zh)
|
2003-07-09 |
2012-02-01 |
生命技术公司 |
检测蛋白-蛋白相互作用的方法
|
US20070224615A1
(en)
*
|
2003-07-09 |
2007-09-27 |
Invitrogen Corporation |
Methods for assaying protein-protein interactions
|
MXPA06002311A
(es)
*
|
2003-09-05 |
2006-05-19 |
Genencor Int |
Epitopos de celulas t cd8+ del virus del papiloma humano (vph).
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
US8188244B2
(en)
*
|
2004-02-11 |
2012-05-29 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Carcinoembryonic antigen fusions and uses thereof
|
EP1735435A1
(en)
*
|
2004-03-18 |
2006-12-27 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving s-ship promoter regions
|
EP1753871B1
(en)
|
2004-05-28 |
2015-07-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
WO2006017279A2
(en)
*
|
2004-07-12 |
2006-02-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions related to identifying protein-protein interactions
|
WO2006135382A2
(en)
|
2004-08-04 |
2006-12-21 |
Chemocentryx, Inc. |
Enzymatic activities in chemokine-mediated inflammation
|
ES2534300T3
(es)
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
BRPI0518933A2
(pt)
|
2004-11-16 |
2008-12-16 |
Crucell Holland B V E Aeras Gl |
adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
|
ES2370885T3
(es)
*
|
2004-12-01 |
2011-12-23 |
Aeras Global Tuberculosis Vaccine Foundation |
Electroporación de mycobacterium y sobreexpresión de antígenos en micobacterias.
|
JP2008538894A
(ja)
*
|
2005-02-11 |
2008-11-13 |
メルク エンド カムパニー インコーポレーテッド |
アデノウイルス血清型26ベクター、核酸およびそれにより製造されたウイルス
|
WO2006090810A2
(en)
|
2005-02-25 |
2006-08-31 |
Oncotherapy Science, Inc. |
Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
|
US7919099B2
(en)
|
2005-02-28 |
2011-04-05 |
Oncotherapy Science, Inc. |
Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
ES2460517T3
(es)
|
2005-07-25 |
2014-05-13 |
Emergent Product Development Seattle, Llc |
Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
|
PT1910839T
(pt)
|
2005-07-27 |
2016-07-14 |
Oncotherapy Science Inc |
Gene tom34 relacionado com o cancro do cólon
|
CA2618508A1
(en)
*
|
2005-08-10 |
2007-02-22 |
Oklahoma Medical Research Foundation |
Truncated memapsin 2 for use for treating alzheimer's disease
|
CA2621982C
(en)
*
|
2005-09-07 |
2017-11-28 |
Jennerex Biotherapeutics Ulc |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
US7919258B2
(en)
*
|
2005-10-07 |
2011-04-05 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Rapid tuberculosis detection method
|
EP2368570A3
(en)
|
2006-01-18 |
2012-05-02 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
CN101438166A
(zh)
*
|
2006-03-14 |
2009-05-20 |
俄勒冈健康科学大学 |
产生针对结核病的免疫应答的方法
|
GB0605474D0
(en)
*
|
2006-03-17 |
2006-04-26 |
Isis Innovation |
Clinical correlates
|
KR101571027B1
(ko)
|
2006-06-12 |
2015-11-23 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
효과기 기능을 갖는 단일쇄 다가 결합 단백질
|
WO2008014484A1
(en)
|
2006-07-27 |
2008-01-31 |
University Of Maryland, Baltimore |
Cellular receptor for antiproliferative factor
|
CN102026645B
(zh)
|
2006-09-15 |
2016-01-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
EP2476697B1
(en)
|
2006-10-17 |
2015-06-17 |
Oncotherapy Science, Inc. |
Peptide vaccines for cancers expressing MPHOSPH1 polypeptides
|
BRPI0717474A2
(pt)
*
|
2006-10-20 |
2014-03-11 |
Arizona Board Of Regentes For And On Behalf Of Arizona State University |
Cianobactéria modificada
|
CA2671264C
(en)
|
2006-11-30 |
2015-11-24 |
Research Development Foundation |
Improved immunoglobulin libraries
|
TWI615403B
(zh)
|
2007-02-21 |
2018-02-21 |
腫瘤療法 科學股份有限公司 |
表現腫瘤相關抗原之癌症的胜肽疫苗
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
TW201425333A
(zh)
|
2007-04-11 |
2014-07-01 |
Oncotherapy Science Inc |
腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
|
EP2155789B1
(en)
|
2007-05-01 |
2013-07-24 |
Research Development Foundation |
Immunoglobulin fc libraries
|
AU2008287195A1
(en)
*
|
2007-07-06 |
2009-02-19 |
Emergent Product Development Seattle, Llc |
Binding peptides having a C-terminally disposed specific binding domain
|
CA2697538C
(en)
|
2007-08-31 |
2019-02-12 |
University Of Chicago |
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
|
EP3085707B1
(en)
|
2007-11-01 |
2019-02-27 |
Mayo Foundation for Medical Education and Research |
Hla-dr binding peptides and their uses
|
JP5677703B2
(ja)
|
2008-01-10 |
2015-02-25 |
リサーチ ディベロップメント ファウンデーション |
Ehrlichiachaffeensisにのためのワクチンおよび診断
|
US20110070601A1
(en)
*
|
2008-01-23 |
2011-03-24 |
Rigshospitalet |
Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
|
PL2245464T3
(pl)
|
2008-01-25 |
2017-08-31 |
Multivir Inc. |
Biomarkery p53
|
RU2010139426A
(ru)
|
2008-03-17 |
2012-04-27 |
Зе Скрипс Ресеч Инститьют (Us) |
Комбинация химического и генетического подходов к получению индуцированных плюрипотентных стволовых клеток
|
WO2009117134A2
(en)
*
|
2008-03-21 |
2009-09-24 |
National Institutes Of Health |
Aerosolized genetic vaccines and methods of use
|
CN102099377A
(zh)
*
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
EP2288379A4
(en)
|
2008-05-19 |
2012-08-08 |
Advaxis |
DOUBLE RELEASE SYSTEM FOR HETEROLOGIST ANTIGENE
|
KR101648019B1
(ko)
|
2008-06-04 |
2016-08-16 |
셀룰러 다이내믹스 인터내셔널, 인코포레이티드 |
비-바이러스 접근법을 사용한 iPS 세포의 생산 방법
|
US8299232B2
(en)
*
|
2008-07-25 |
2012-10-30 |
Department Of Biotechnology |
Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis
|
US9175268B2
(en)
|
2008-08-12 |
2015-11-03 |
Cellular Dynamics International, Inc. |
Methods for the production of iPS cells
|
US8912146B2
(en)
|
2008-08-18 |
2014-12-16 |
University Of Maryland, Baltimore |
Derivatives of APF and methods of use
|
US8512944B2
(en)
|
2008-08-27 |
2013-08-20 |
Oncotherapy Science, Inc. |
PRMT1 for target genes of cancer therapy and diagnosis
|
JP2012504660A
(ja)
|
2008-10-06 |
2012-02-23 |
ユニバーシティ オブ シカゴ |
細菌eap、empおよび/またはadsaタンパク質に関連する組成物および方法
|
WO2010048252A1
(en)
*
|
2008-10-23 |
2010-04-29 |
Intervet International B.V. |
Lawsonia intracellularis vaccines
|
TWI500932B
(zh)
|
2008-12-05 |
2015-09-21 |
Oncotherapy Science Inc |
Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
|
JP5651125B2
(ja)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Mek阻害剤に対する耐性を付与するmek突然変異
|
EP3312269A1
(en)
|
2008-12-17 |
2018-04-25 |
The Scripps Research Institute |
Generation and maintenance of stem cells
|
EP2379720B1
(en)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Mir-21 promoter driven targeted cancer therapy
|
TWI469791B
(zh)
|
2009-02-18 |
2015-01-21 |
Oncotherapy Science Inc |
Foxm1胜肽以及含此胜肽之疫苗
|
ES2617434T3
(es)
|
2009-03-18 |
2017-06-19 |
Oncotherapy Science, Inc. |
Péptidos NEIL3 y vacunas que incluyen los mismos
|
KR20170102039A
(ko)
|
2009-04-03 |
2017-09-06 |
유니버시티 오브 시카고 |
단백질 A(SpA) 변이체와 관련된 조성물 및 방법
|
EP2424885B1
(en)
|
2009-04-28 |
2016-03-23 |
Vanderbilt University |
Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
|
TWI507204B
(zh)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l胜肽與含此胜肽之疫苗
|
AU2010254811B2
(en)
|
2009-06-05 |
2015-02-19 |
FUJIFILM Cellular Dynamics, Inc. |
Reprogramming T cells and hematopoietic cells
|
US20110053803A1
(en)
|
2009-08-26 |
2011-03-03 |
Xin Ge |
Methods for creating antibody libraries
|
ES2848650T3
(es)
|
2009-09-14 |
2021-08-11 |
Sillajen Biotherapeutics Inc |
Terapia combinada contra el cáncer con virus vaccinia oncolítico
|
CN103403026B
(zh)
|
2009-09-25 |
2016-05-11 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1中和抗体及其用途
|
EP2482834A4
(en)
*
|
2009-09-30 |
2013-07-10 |
Univ Saint Louis |
PEPTIDES TRIGGERING SUB-TYPICAL HETERO RESPONSES OF T-CELLS AGAINST FLU
|
JP5808331B2
(ja)
|
2009-10-16 |
2015-11-10 |
ザ スクリプス リサーチ インスティテュート |
多能性細胞の誘導法
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
CN102858959B
(zh)
|
2009-12-10 |
2016-02-24 |
渥太华医院研究院 |
溶瘤弹状病毒
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
US10080799B2
(en)
|
2010-02-12 |
2018-09-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
ES2674682T3
(es)
|
2010-02-25 |
2018-07-03 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
US20130052221A1
(en)
|
2010-02-26 |
2013-02-28 |
The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services |
Dna-protein vaccination protocols
|
WO2011108930A1
(en)
|
2010-03-04 |
2011-09-09 |
Interna Technologies Bv |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
|
CA2792910A1
(en)
|
2010-03-11 |
2011-09-15 |
Yusuke Nakamura |
Hjurp peptides and vaccines including the same
|
CN102959076B
(zh)
|
2010-03-31 |
2015-09-16 |
斯克里普斯研究所 |
重编程细胞
|
TW201627003A
(zh)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
Ect2胜肽及含此胜肽之疫苗
|
JP2013523818A
(ja)
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
WO2011126976A1
(en)
|
2010-04-07 |
2011-10-13 |
Vanderbilt University |
Reovirus vaccines and methods of use therefor
|
DK2560672T3
(da)
|
2010-04-19 |
2014-03-17 |
Res Dev Foundation |
RTEF-1-varianter samt deres anvendelser
|
ES2873933T3
(es)
|
2010-06-09 |
2021-11-04 |
Dana Farber Cancer Inst Inc |
Una mutación de MEK1 que confiere resistencia a inhibidores de RAF y de MEK
|
ES2685171T3
(es)
|
2010-06-14 |
2018-10-05 |
The Scripps Research Institute |
Reprogramación de células a un nuevo destino
|
CA2802087A1
(en)
|
2010-06-15 |
2011-12-22 |
Cellular Dynamics International, Inc. |
A compendium of ready-built stem cell models for interrogation of biological response
|
EP2582794B2
(en)
|
2010-06-15 |
2024-04-24 |
FUJIFILM Cellular Dynamics, Inc. |
Generation of induced pluripotent stem cells from small volumes of peripheral blood
|
KR20130093084A
(ko)
|
2010-07-02 |
2013-08-21 |
더 유니버시티 오브 시카고 |
단백질 A(SpA) 변이체와 관련된 조성물 및 방법
|
NZ719520A
(en)
|
2010-07-06 |
2017-07-28 |
Int Tech Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
CA2804595C
(en)
|
2010-07-07 |
2018-11-13 |
Cellular Dynamics International, Inc. |
Endothelial cell production by programming
|
CA2806858C
(en)
|
2010-08-04 |
2021-06-15 |
Cellular Dynamics International, Inc. |
Reprogramming immortalized b cells
|
JP5793194B2
(ja)
|
2010-09-09 |
2015-10-14 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
感染防御ブドウ球菌抗原が関与する方法および組成物
|
EP3536337A1
(en)
|
2010-09-22 |
2019-09-11 |
The Regents of the University of Colorado, a body corporate |
Therapeutic applications of smad7
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
EP2622065B1
(en)
|
2010-10-01 |
2016-09-07 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Manipulation of stem cell function by p53 isoforms
|
US9732319B2
(en)
|
2010-12-22 |
2017-08-15 |
Fate Therapeutics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
JP6121910B2
(ja)
|
2011-01-04 |
2017-04-26 |
シラジェン バイオセラピューティクス インコーポレイテッド |
腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
RU2539035C2
(ru)
*
|
2011-01-13 |
2015-01-10 |
Амир Закиевич Максютов |
Профилактическая или терапевтическая полиэпитопная противотуберкулезная вакцинная конструкция, обеспечивающая индукцию клеточного иммунного ответа cd4+ или cd8+ т-лимфоцитов
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
WO2012109208A2
(en)
|
2011-02-08 |
2012-08-16 |
Cellular Dynamics International, Inc. |
Hematopoietic precursor cell production by programming
|
CA2829960A1
(en)
|
2011-03-11 |
2012-09-20 |
John Rothman |
Listeria-based adjuvants
|
EP3406628A1
(en)
|
2011-04-08 |
2018-11-28 |
Evaxion Biotech ApS |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
WO2012156535A1
(en)
|
2011-05-19 |
2012-11-22 |
Fundación Progreso Y Salud |
Highly inducible dual-promoter lentiviral tet-on system
|
ES2627529T3
(es)
|
2011-06-08 |
2017-07-28 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Composiciones para tratamiento de glioblastoma
|
WO2013009825A1
(en)
|
2011-07-11 |
2013-01-17 |
Cellular Dynamics International, Inc. |
Methods for cell reprogramming and genome engineering
|
US9725490B2
(en)
|
2011-07-29 |
2017-08-08 |
Tokushima University |
ERAP1-derived peptide and use thereof
|
CN103732743B
(zh)
|
2011-08-12 |
2017-03-15 |
肿瘤疗法科学股份有限公司 |
Mphosph1肽及包含它们的疫苗
|
CN103906535B
(zh)
|
2011-08-15 |
2017-07-14 |
芝加哥大学 |
与葡萄球菌蛋白a的抗体相关的组合物和方法
|
US20130101664A1
(en)
|
2011-08-18 |
2013-04-25 |
Donald W. Kufe |
Muc1 ligand traps for use in treating cancers
|
JP2013046596A
(ja)
*
|
2011-08-29 |
2013-03-07 |
Alpha-Nano-Medica Co Ltd |
新規な複合体、それを含有する医薬及び癌の治療方法
|
US9273102B2
(en)
|
2011-10-12 |
2016-03-01 |
Niels Iversen Møller |
Peptides derived from Campylobacter jejuni and their use in vaccination
|
BR112014009176B1
(pt)
|
2011-10-28 |
2022-08-30 |
Oncotherapy Science, Inc |
Composição para indução de linfócito t citotóxico (ctl), uso no tratamento e profilaxia de câncer e indução de resposta imune contra câncer e métodos in vitro para indução de ctl
|
US10174314B2
(en)
|
2011-12-22 |
2019-01-08 |
Interna Technologies B.V. |
MiRNA for treating head and neck cancer
|
AU2013232291B8
(en)
|
2012-03-12 |
2016-07-21 |
Advaxis, Inc. |
Suppressor cell function inhibition following listeria vaccine treatment
|
CA2910320A1
(en)
|
2012-04-26 |
2013-10-31 |
University Of Chicago |
Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
|
EP3805395A1
(en)
|
2012-04-26 |
2021-04-14 |
University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
EP2872531A4
(en)
|
2012-07-10 |
2016-04-06 |
Oncotherapy Science Inc |
LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
|
WO2014010231A1
(en)
|
2012-07-10 |
2014-01-16 |
Oncotherapy Science, Inc. |
Kif20a epitope peptides for th1 cells and vaccines containing the same
|
AU2013317194B2
(en)
|
2012-09-11 |
2018-07-12 |
Oncotherapy Science, Inc. |
UBE2T peptides and vaccines containing the same
|
WO2014065945A1
(en)
|
2012-10-23 |
2014-05-01 |
The Board Of Regents Of The University Of Texas System |
Antibodies with engineered igg fc domains
|
US10201556B2
(en)
|
2012-11-06 |
2019-02-12 |
Interna Technologies B.V. |
Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
|
WO2014116721A1
(en)
|
2013-01-22 |
2014-07-31 |
The Arizona Board Of Regents For And On Behalf Of Arizona State University |
Geminiviral vector for expression of rituximab
|
EP2958990B1
(en)
|
2013-02-20 |
2019-10-16 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
US10363293B2
(en)
|
2013-02-21 |
2019-07-30 |
Turnstone Limited Partnership |
Vaccine composition
|
WO2014130770A1
(en)
|
2013-02-22 |
2014-08-28 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
EP2961386B1
(en)
|
2013-02-28 |
2019-07-10 |
The General Hospital Corporation |
Mirna profiling compositions and methods of use
|
CN105358704B
(zh)
|
2013-03-08 |
2020-01-03 |
科罗拉多大学董事会 |
Ptd-smad7治疗剂
|
TWI658049B
(zh)
|
2013-03-12 |
2019-05-01 |
腫瘤療法 科學股份有限公司 |
Kntc2胜肽及含此胜肽之疫苗
|
WO2014140301A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Université De Genève |
Anti-mycobacterial vaccines
|
EP2978450B1
(en)
|
2013-03-27 |
2018-09-19 |
ImmunoVaccine Technologies Inc. |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
RU2520078C1
(ru)
*
|
2013-04-25 |
2014-06-20 |
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) |
СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
|
CA2923857A1
(en)
|
2013-09-09 |
2015-03-12 |
Figene, Llc |
Gene therapy for the regeneration of chondrocytes or cartilage type cells
|
CA2929555A1
(en)
|
2013-11-08 |
2015-05-14 |
Baylor Research Institute |
Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
|
US20170002064A1
(en)
|
2013-11-08 |
2017-01-05 |
The Board Of Regents Of The University Of Texas System |
Vh4 antibodies against gray matter neuron and astrocyte
|
EP4227685A3
(en)
|
2013-12-03 |
2024-02-28 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
KR102448454B1
(ko)
|
2014-01-29 |
2022-09-28 |
다나-파버 캔서 인스티튜트 인크. |
Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체
|
US10214741B2
(en)
|
2014-02-14 |
2019-02-26 |
University Of Utah Research Foundation |
Methods and compositions for inhibiting retinopathy of prematurity
|
WO2015130783A1
(en)
|
2014-02-25 |
2015-09-03 |
Research Development Foundation |
Sty peptides for inhibition of angiogenesis
|
EP3805369A1
(en)
|
2014-03-04 |
2021-04-14 |
Fate Therapeutics, Inc. |
Improved reprogramming methods and cell culture platforms
|
US20170107486A1
(en)
|
2014-04-21 |
2017-04-20 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
RU2699543C2
(ru)
|
2014-08-04 |
2019-09-06 |
Онкотерапи Сайенс, Инк. |
Пептид, полученный из cdca1, и содержащая его вакцина
|
MX2017001649A
(es)
|
2014-08-04 |
2017-04-27 |
Oncotherapy Science Inc |
Peptido derivado de koc1 y vacuna que lo incluye.
|
RU2700881C2
(ru)
|
2014-08-04 |
2019-09-23 |
Онкотерапи Сайенс, Инк. |
Пептид, полученный из urlc10, и содержащая его вакцина
|
US20180363070A9
(en)
|
2014-08-12 |
2018-12-20 |
Univ Wayne State |
Systems and methods to detect stem cell stress and uses thereof
|
WO2016075305A2
(en)
|
2014-11-13 |
2016-05-19 |
Evaxion Biotech Aps |
Peptides derived from acinetobacter baumannii and their use in vaccination
|
EP3242883A4
(en)
|
2015-01-06 |
2018-10-17 |
ImmunoVaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
EP4279080A3
(en)
|
2015-01-12 |
2024-02-21 |
Evaxion Biotech A/S |
Treatment and prophylaxis of k. pneumoniae infection
|
WO2016120697A1
(en)
|
2015-01-28 |
2016-08-04 |
Sabic Global Technologies B.V. |
Methods and compositions for high-efficiency production of biofuel and/or biomass
|
WO2016130516A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US11421229B2
(en)
|
2015-02-20 |
2022-08-23 |
Baylor College Of Medicine |
p63 inactivation for the treatment of heart failure
|
EP3294755B1
(en)
|
2015-05-13 |
2023-08-23 |
The United States of America as represented by the Secretary of the Department of Health and Human Services |
Methods and compositions for inducing an immune response using conserved element constructs
|
WO2016196366A1
(en)
|
2015-05-29 |
2016-12-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Extension of replicative lifespan in diseases of premature aging using p53 isoforms
|
EP3317295B1
(en)
|
2015-07-04 |
2022-05-18 |
Evaxion Biotech A/S |
Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
AU2016335731B2
(en)
|
2015-10-08 |
2021-05-06 |
Oncotherapy Science, Inc. |
FOXM1-derived peptide, and vaccine including same
|
AU2016338680B2
(en)
|
2015-10-16 |
2022-11-17 |
Fate Therapeutics, Inc. |
Platform for the induction and maintenance of ground state pluripotency
|
WO2017070337A1
(en)
|
2015-10-20 |
2017-04-27 |
Cellular Dynamics International, Inc. |
Methods for directed differentiation of pluripotent stem cells to immune cells
|
JP6983771B2
(ja)
|
2015-10-30 |
2021-12-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
幹細胞からt細胞を作製する方法および該t細胞を用いた免疫療法的方法
|
WO2017079202A1
(en)
|
2015-11-02 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Methods of cd40 activation and immune checkpoint blockade
|
US20190038713A1
(en)
|
2015-11-07 |
2019-02-07 |
Multivir Inc. |
Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
CA3004438A1
(en)
|
2015-11-09 |
2017-05-18 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
WO2017144523A1
(en)
|
2016-02-22 |
2017-08-31 |
Evaxion Biotech Aps |
Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
|
US20190177391A1
(en)
|
2016-03-31 |
2019-06-13 |
Baylor Research Institute |
Angiopoietin-like protein 8 (angptl8)
|
WO2017216384A1
(en)
|
2016-06-17 |
2017-12-21 |
Evaxion Biotech Aps |
Vaccination targeting ichthyophthirius multifiliis
|
US11091775B2
(en)
*
|
2016-06-22 |
2021-08-17 |
Oregon Health And Science University |
Recombinant cytomegalovirus vectors as vaccines for tuberculosis
|
WO2017220787A1
(en)
|
2016-06-24 |
2017-12-28 |
Evaxion Biotech Aps |
Vaccines against aearomonas salmonicida infection
|
US20180030478A1
(en)
|
2016-07-01 |
2018-02-01 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2018015575A1
(en)
|
2016-07-22 |
2018-01-25 |
Evaxion Biotech Aps |
Chimeric proteins for inducing immunity towards infection with s. aureus
|
US9963498B2
(en)
|
2016-08-18 |
2018-05-08 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
|
AU2017319702A1
(en)
|
2016-09-02 |
2019-04-11 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
CN110050061A
(zh)
|
2016-10-05 |
2019-07-23 |
富士胶片细胞动力公司 |
从具有MeCP2破坏的诱导多能干细胞生成成熟谱系
|
JP7212615B2
(ja)
|
2016-10-05 |
2023-01-25 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法
|
EP3551226A1
(en)
|
2016-12-12 |
2019-10-16 |
MultiVir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018127545A1
(en)
|
2017-01-05 |
2018-07-12 |
Evaxion Biotech Aps |
Vaccines targeting pseudomonas aeruginosa
|
JP7181219B2
(ja)
|
2017-04-18 |
2022-11-30 |
フジフィルム セルラー ダイナミクス,インコーポレイテッド |
抗原特異的免疫エフェクター細胞
|
EP3704250A1
(en)
|
2017-11-03 |
2020-09-09 |
InteRNA Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
WO2019099493A1
(en)
|
2017-11-14 |
2019-05-23 |
Henry Ford Health System |
Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
|
RU2020124404A
(ru)
|
2018-01-05 |
2022-01-24 |
Оттава Хоспитл Рисерч Инститьют |
Векторы на основе модифицированного вируса осповакцины
|
WO2019145399A1
(en)
|
2018-01-24 |
2019-08-01 |
Evaxion Biotech Aps |
Vaccines for prophylaxis of s. aureus infections
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
SG11202009697RA
(en)
|
2018-03-30 |
2020-10-29 |
Univ Geneve |
Micro rna expression constructs and uses thereof
|
TW202023581A
(zh)
|
2018-08-02 |
2020-07-01 |
日商腫瘤療法 科學股份有限公司 |
來自cdca1的胜肽及含有此的疫苗
|
SG11202102058UA
(en)
|
2018-08-30 |
2021-03-30 |
Tenaya Therapeutics Inc |
Cardiac cell reprogramming with myocardin and ascl1
|
US20220000932A1
(en)
|
2018-09-28 |
2022-01-06 |
Henry Ford Health System |
Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
|
WO2020083904A1
(en)
|
2018-10-22 |
2020-04-30 |
Evaxion Biotech Aps |
Vaccines targeting m. catharrhalis
|
WO2020111167A1
(ja)
|
2018-11-30 |
2020-06-04 |
国立大学法人徳島大学 |
Big3-phb2相互作用阻害phb2由来ペプチドを含む乳がん治療薬
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
EP3931206A1
(en)
|
2019-02-27 |
2022-01-05 |
Evaxion Biotech ApS |
Vaccines targeting h. influenzae
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
AU2020317009A1
(en)
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
US20210147525A1
(en)
|
2019-10-18 |
2021-05-20 |
The Regents Of The University Of California |
Methods and compositions for treating pathogenic blood vessel disorders
|
KR102237349B1
(ko)
|
2019-10-23 |
2021-04-07 |
한국과학기술연구원 |
니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
EP4087593A1
(en)
|
2020-01-06 |
2022-11-16 |
Evaxion Biotech A/S |
Vaccines targeting neisseria gonorrhoeae
|
JP2023515672A
(ja)
|
2020-03-02 |
2023-04-13 |
テナヤ セラピューティクス, インコーポレイテッド |
心筋細胞発現マイクロrnaによる遺伝子ベクター制御
|
JP2023520359A
(ja)
|
2020-03-25 |
2023-05-17 |
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム |
放射性核種イメージングのためのレポーター系
|
WO2021240240A1
(en)
|
2020-05-27 |
2021-12-02 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
KR20230019453A
(ko)
|
2020-05-29 |
2023-02-08 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
망막 색소 상피 세포 및 광수용체의 이중 세포 응집체 및 이의 사용 방법
|
CN116323677A
(zh)
|
2020-05-29 |
2023-06-23 |
富士胶片细胞动力公司 |
视网膜色素上皮和光感受器双层及其用途
|
WO2022053130A1
(en)
|
2020-09-09 |
2022-03-17 |
Sid Alex Group, S.R.O. |
Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
|
JP2024508088A
(ja)
|
2021-02-09 |
2024-02-22 |
ユニバーシティ オブ ヒューストン システム |
全身送達及び抗腫瘍活性の向上のための腫瘍溶解性ウイルス
|
WO2022175815A1
(en)
|
2021-02-19 |
2022-08-25 |
Pfizer Inc. |
Methods of protecting rna
|
CN117242173A
(zh)
|
2021-05-03 |
2023-12-15 |
安斯泰来再生医药协会 |
产生成熟角膜内皮细胞的方法
|
AU2022270117A1
(en)
|
2021-05-07 |
2023-11-02 |
Astellas Institute For Regenerative Medicine |
Methods of generating mature hepatocytes
|
US20220389436A1
(en)
|
2021-05-26 |
2022-12-08 |
FUJIFILM Cellular Dynamics, Inc. |
Methods to prevent rapid silencing of genes in pluripotent stem cells
|
EP4366762A1
(en)
|
2021-07-05 |
2024-05-15 |
Evaxion Biotech A/S |
Vaccines targeting neisseria gonorrhoeae
|
WO2023089556A1
(en)
|
2021-11-22 |
2023-05-25 |
Pfizer Inc. |
Reducing risk of antigen mimicry in immunogenic medicaments
|
WO2023144779A1
(en)
|
2022-01-28 |
2023-08-03 |
Pfizer Inc. |
Coronavirus antigen variants
|
WO2023178191A1
(en)
|
2022-03-16 |
2023-09-21 |
University Of Houston System |
Persistent hsv gene delivery system
|
GB202205265D0
(en)
|
2022-04-11 |
2022-05-25 |
Mogrify Ltd |
Cell conversion
|
WO2023213393A1
(en)
|
2022-05-04 |
2023-11-09 |
Evaxion Biotech A/S |
Staphylococcal protein variants and truncates
|
GB202206507D0
(en)
|
2022-05-04 |
2022-06-15 |
Antion Biosciences Sa |
Expression construct
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
US20240003871A1
(en)
|
2022-06-29 |
2024-01-04 |
FUJIFILM Cellular Dynamics, Inc. |
Ipsc-derived astrocytes and methods of use thereof
|